ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0317

“No matter how great my doctor is, he hasn’t had a knee replacement, he doesn’t understand all that pain” Program Evaluation of the Moving Well Peer Coach Intervention for Total Knee Replacement
Abstract Number: 1052

“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use
Abstract Number: 0189

“Try it, you’ll love it”: Patterns of AI Scribes Use Among Rheumatologists
Abstract Number: 0359

“VA is a slow-moving ship, but you can steer it”: Clinician Views on Navigating Shared Decision-Making and Anticipated Use of an RA Decision Aid
Abstract Number: 1956

68Ga-FAPI-04 and 18F-FDG PET/ CT in MDA5 dermatomyositis-associated interstitial lung disease: a single-center, pilot study
Abstract Number: 1375

86-96% of rheumatoid arthritis (RA) patients with RA who have 0 or 1 swollen joint or tender joint but are classified as moderate/high on RA indices have 1-9 comorbidities recognized on a multidimensional health assessment questionnaire (MDHAQ)
Abstract Number: 0446

A Balancing Act: The Interplay Between Resilience and Frailty in Rheumatoid Arthritis
Abstract Number: 0613

A Baseline Kidney Biopsy Is Not Always Feasible in Incident Lupus Nephritis: Insights From an Inception Cohort
Abstract Number: 2054

A Changing Paradigm: Reassessing the Role of Muscle Biopsy in Idiopathic Inflammatory Myopathies in a Single-Center Cohort
Abstract Number: 1287

A clear pattern of clinical presentation in juvenile systemic scleroderma is associated with interstitial lung disease
Abstract Number: 1668

A clinically validated assay for rapid determination of type I and type II interferon activity in pediatric inflammatory diseases
Abstract Number: 1406

A Combined Score of Facet Joint Ankylosis and Syndesmophyte Development Correlates Well with Spinal Mobility in Axial Spondyloarthritis
Abstract Number: 1405

A Combined Score of Syndesmophytes and Facet Joint Ankylosis Improves Sensitivity to Spinal Structural Damage Progression in Axial Spondyloarthritis
Abstract Number: 0719

A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis
Abstract Number: 1395

A Comparative Study of Yao Syndrome and Primary Sjögren’s Syndrome

1
2
3
…
181
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].